ReviewProbiotics and antimicrobial proteins2017
Current Perspectives on Antihypertensive Probiotics.
Review in Probiotics and antimicrobial proteins, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 84 citations in OpenAlex.
- Food-derived bioactive peptides: health benefits, structure‒activity relationships, and translational prospects.Journal of Zhejiang University. Science. B · 2025Review
- The Effects of Probiotics Consumption on Blood Pressure, Lipid Profile, Glycemic Indices, and Inflammatory Parameters in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Food science & nutrition · 2025Review
- Causal Associations Between the Gut Microbiota and Hypertension-Related Traits Through Mendelian Randomization: A Cross-Sectional Cohort Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease.Nutrients · 2024Review
- Gut-joint axis: Oral Probiotic ameliorates Osteoarthritis.Journal of traditional and complementary medicine · 2024Article
- Gut microbiota and hypertension: a bibliometric analysis of recent research (2014-2023).Frontiers in nutrition · 2023Review
- Food Peptides, Gut Microbiota Modulation, and Antihypertensive Effects.Molecules (Basel, Switzerland) · 2022Review
- Regulatory effect of gut microbes on blood pressure.Animal models and experimental medicine · 2022Review
- Evaluation of the effect of Lactiplantibacillus pentosus SN001 fermentation on arsenic accumulation and antihypertensive effect of Sargassum horneri in vivo.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Enhancing the Biological Activities of Food Protein-Derived Peptides Using Non-Thermal Technologies: A Review.Foods (Basel, Switzerland) · 2022Review
- Bioactive peptides produced by engineered probiotics and other food-grade bacteria: A review.Food chemistry: X · 2022Article
- Antihypertensive and Probiotic Effects of Hidakakombu (Foods (Basel, Switzerland) · 2021Article
- Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke.Nutrients · 2021Review
- Systematic Network and Meta-analysis on the Antiviral Mechanisms of Probiotics: A Preventive and Treatment Strategy to Mitigate SARS-CoV-2 Infection.Probiotics and antimicrobial proteins · 2021Article
- Unveiling Putative Functions of Mucus Proteins and Their Tryptic Peptides in Seven Gastropod Species Using Comparative Proteomics and Machine Learning-Based Bioinformatics Predictions.Molecules (Basel, Switzerland) · 2021Article
- Pien Tze Huang (PZH) as a Multifunction Medicinal Agent in Traditional Chinese Medicine (TCM): a review on cellular, molecular and physiological mechanisms.Cancer cell international · 2021Review
- Use ofInternational journal of food science · 2021Article
- Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.Frontiers in medicine · 2021Review
- Untargeted Metabolomics of Fermented Rice Using UHPLC Q-TOF MS/MS Reveals an Abundance of Potential Antihypertensive Compounds.Foods (Basel, Switzerland) · 2020Article
- Therapeutic Delivery of Ang(1-7) via Genetically Modified Probiotic: A Dosing Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a major risk factor for cardiovascular diseases. Optimizing blood pressure results in an overall health outcome. Over the years, the gut microbiota has been found to play a significant role in host metabolic processes, immunity, and physiology. Dietary strategies have therefore become a target for restoring disturbed gut microbiota to treat metabolic diseases. Probiotics and their fermented products have been shown in many studies to lower blood pressure by suppressing nitrogen oxide production in microphages, reducing reactive oxygen species, and enhancing dietary calcium absorption. Other studies have shown that hypertension could be caused by many factors including hypercholesterolemia, chronic inflammation, and inconsistent modulation of the renin-angiotensin system. This review discusses the antihypertensive roles of probiotics and their fermented products via the reduction of serum cholesterol levels, anti-inflammation, and inhibition of angiotensin-converting enzyme. The ability of recombinant probiotics to reduce high blood pressure has also been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.